BMO reiterates Vertex stock rating on positive trial data

BMO Capital has maintained its Outperform rating and set a $600 per share price target for Vertex Pharmaceuticals Inc. (VRTX) following promising clinical trial results of their drug inaxaplin. The stock is currently priced at $523.42, with a market capitalization of $132 billion, and has generated a 33% return over the past year.

The AMPLIFIED trial demonstrated that inaxaplin reduced urine albumin to creatinine ratio (UACR) by 42.7% in patients with AMKD (Alport syndrome) and modest proteinuria, extending efficacy beyond the severe-proteinuria population studied in the AMPLITUDE trial. Notably, a Type 2 diabetes cohort in the study experienced a 17.3% UACR reduction.

BMO Capital believes the results are encouraging, particularly in a more challenging disease setting. The AMPLITUDE trial is fully enrolled, with interim data expected in early 2027. While InvestingPro analysis suggests the stock may be overvalued compared to its Fair Value estimate, analysts highlight Vertex's drug development potential, particularly beyond its cystic fibrosis franchise.

Other firms, including Stifel, RBC Capital, and Bernstein, have also offered positive outlooks on Vertex's stock, maintaining various ratings and price targets.